How has Aclaris Therapeutics's other commercial liabilities changed year-over-year?

Aclaris Therapeutics's other commercial liabilities decreased by 31.2% year-over-year, from $8.57M to $5.9M.

What is the long-term trend for Aclaris Therapeutics's other commercial liabilities?

Over 5 years (2020 to 2025), Aclaris Therapeutics's other commercial liabilities has grown at a 8.3% compound annual growth rate (CAGR), from $5.91M to $8.79M.

Aclaris Therapeutics ACRS Other Commercial Liabilities

Other Commercial Liabilities at other companies

IncyteINCY

——

Corvus PharmaceuticalsCRVS

——

Kymera TherapeuticsKYMR

——

Vor BiopharmaVOR

——

Cullinan Therapeutics, Inc.CGEM

——

AnaptysBio, Inc.ANAB

——

Other financials

Income statement

See full

Revenue$2.0M+37.2%

Gross profit$1.6M+68.7%

Operating income-$22.2M-22.7%

Net income-$19.8M-31.4%

EPS (diluted)-$0.15-25.0%

Balance sheet

See full

Cash & equivalents$28.7M-5.6%

Total debt$2.0M-20.1%

Total equity$143.6M-0.3%

Total assets$198.7M+0.3%

Cash flow

See full

Operating cash flow-$18.1M-39.0%

CapEx$13.0K-69.8%

Free cash flow-$18.2M-38.6%

Valuation

See full

Market cap$685.75M+337%

Enterprise value$659.07M+410%

P/S82×+73.1×

Profitability

See full

Gross margin76.3%-9.7pp

Operating margin-961.9%+259pp

Net margin-832.6%+132pp

FCF margin-624.9%—

Returns & leverage

See full

Return on equity-48.4%-15.4pp

Debt / equity0×0.0×

Current ratio4×-1.0×

Where this comes from

Reported directly by Aclaris Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:AccruedLiabilitiesCurrent.

The official record: Aclaris Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Aclaris Therapeutics's other commercial liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Aclaris Therapeutics's other commercial liabilities?: Aclaris Therapeutics (ACRS) reported other commercial liabilities of $5.9M in Q1 2026.
How has Aclaris Therapeutics's other commercial liabilities changed year-over-year?: Aclaris Therapeutics's other commercial liabilities decreased by 31.2% year-over-year, from $8.57M to $5.9M.
What is the long-term trend for Aclaris Therapeutics's other commercial liabilities?: Over 5 years (2020 to 2025), Aclaris Therapeutics's other commercial liabilities has grown at a 8.3% compound annual growth rate (CAGR), from $5.91M to $8.79M.